A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Subjects With Solid Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 26 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; GS-9716 (Primary) ; Sacituzumab govitecan (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Gilead Sciences

29 Aug 2023 Planned End Date changed from 1 May 2028 to 1 Jan 2027.
29 Aug 2023 Planned primary completion date changed from 1 Mar 2027 to 1 Jan 2027.
31 Jul 2023 Number of treatment arms have been reduced from 12 to 6 by the removal of 3 arms from part B and 3 arms from part C. One primary end-point is removed and patient enrollment is reduced. All the specific indication are removed from indications and Gemcitabine is removed from drugs.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com